Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2014

01-04-2014 | R&D Insight Report

Ipragliflozin: First Global Approval

Authors: Raewyn M. Poole, Rosselle T. Dungo

Published in: Drugs | Issue 5/2014

Login to get access

Abstract

Ipragliflozin (Suglat® [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatment of type 2 diabetes mellitus. Ipragliflozin has received its first global approval in this indication in Japan, for use as monotherapy or in combination with another antihyperglycaemic agent (metformin, pioglitazone, a sulfonylurea, an α-glucosidase inhibitor, a dipeptidylpeptidase-4 inhibitor or nateglinide). Ipragliflozin is the first SGLT2 inhibitor to be approved in Japan. This article summarizes the milestones in the development of ipragliflozin leading to this first approval for the treatment of type 2 diabetes mellitus.
Literature
1.
Imamura M, Nakanishi K, Suzuki T, et al. Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012;20(10):3263–79.PubMedCrossRef
2.
Veltkamp SA, Kadokura T, Krauwinkel WJJ, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31(12):839–51.PubMedCrossRef
3.
Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12(3):230–8.PubMedCrossRef
4.
Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65(3):317–27.PubMedCrossRef
5.
Cangoz S, Chang YY, Chempakaseril SJ, et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther. 2013;38(5):350–9.PubMedCrossRef
6.
Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2(4):172–82.CrossRef
7.
Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1–3):246–55.PubMedCrossRef
8.
Astellas Pharma Inc. Approval of Suglat(Rm) tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes, in Japan. Media Release. 2014.
9.
10.
11.
Astellas Pharma Inc., Msd K.K. Astellas and MSD enter co-promotion agreement in Japan for ipragliflozin, SGLT2 inhibitor for treatment of type 2 diabetes. Media Release. 2013.
12.
Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedebergs Arch Pharmacol. 2012;385(4):423–36.PubMedCrossRef
13.
Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36–44.PubMedCrossRef
14.
Smulders RA, Leeflang S, Schliess F, et al. The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus. Diabetologia. 2013;56(Suppl):S399–400.
15.
Akiyama N, Kashiwagi A, Kadokura T, et al. ASP1941, a novel, selective SGLT2 inhibitor improved both fasting and postprandial glucose levels in Japanese type 2 diabetic patients. Diabetes. 2011;60(Suppl 1):A280–1.
16.
Zhang W, Smulders R, Abeyratne A, et al. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. Clin Ther. 2013;35(8):1150–61.e3.
17.
Zhang W, Krauwinkel WJJ, Keirns J, et al. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. Clin Drug Investig. 2013;33(7):489–96.PubMedCrossRef
18.
Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219–27.PubMedCrossRef
19.
Kadokura T, Ishikawa H, Nakajo I, et al. The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ipragliflozin (ASP1941) in Japanese type 2 diabetes mellitus patients. Diabetologia. 2011;54:S346.
20.
Nakajo I, Taniuchi Y, Yoshida S, et al. Drug interaction study of ipragliflozin and migitol in healthy Japanese subjects. Clin Pharmacol Ther. 2012;91:S11.
21.
Zhang W, et al. Lack of pharmacokinetic interactions between Asp1941, a selective sodium glucose co-transporter 2 (Sglt2) inhibitor, and pioglitazone in healthy subjects. Clin Pharmacol Ther. 2011;89(Suppl 1):S82.
22.
Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14(10):937–43.PubMedCrossRef
23.
Zhang W, et al. Lack of pharmacokinetic interactions between Asp 1941, a selective sodium glucose co-transporter 2 (Sglt2) inhibitor, and sitagliptin in healthy subjects. Clin Pharmacol Ther. 2011;89(Suppl 1):S81–2.
24.
Veltkamp SA, Van Dijk J, Krauwinkel WJ, et al. Lack of pharmacokinetic and pharmacodynamic interaction between ipragliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, and glimepiride in healthy subjects. Clin Pharmacol Ther. 2012;91:S11–2.
25.
Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012;34(8):1761–71.PubMedCrossRef
26.
Goto K, Kashiwagi A, Kazuta K, et al. Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: Illuminate study. Diabetes. 2012;61:A269.
27.
Kashiwagi A, Shiga T, Akiyama N, et al. Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone. Diabetologia. 2012;55:S302–3.
28.
Wilding JPH, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–9.PubMedCrossRef
29.
Kashiwagi A, Takinami Y, Kazuta K, et al. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia. 2011;54:S68–9.
30.
Kawano H, Kashiwagi A, Kazuta K, et al. Long-term safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus: Ignite. Diabetes. 2012;61:A610.CrossRef
31.
Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27(3):268–73.PubMedCrossRef
Metadata
Title
Ipragliflozin: First Global Approval
Authors
Raewyn M. Poole
Rosselle T. Dungo
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0204-x

Other articles of this Issue 5/2014

Drugs 5/2014 Go to the issue

Current Opinion

Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?

Systematic Review

Meta-Review: Adverse Effects of Inhaled Corticosteroids Relevant to Older Patients

Current Opinion

Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis

Adis Drug Evaluation

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

Adis Drug Evaluation

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Adis Drug Evaluation

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus